Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study Protocol M10-221 The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

NCT00616902 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00616902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00616902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study Protocol M10-221 The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
Lead sponsor
Abbott
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2009
Completion date
May 31, 2009
Enrollment
12 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease (ckd) stage 5, hypertrophy, left ventricular